Evaluation of the Simplified Treat And Extend Regimen Using Ranibizumab in Exudative Age Related Macular Degeneration
- Sponsor
- Mie University
- Study ID
- NCT02328209
- Status
- Unknown
Conditions
- Exudative Age-related Macular Degeneration
Eligibility Criteria
- Sex
- ALL
- Age
- 50 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- ranibizumab — DRUG0.5mg/0.05ml, intravitreal injection, frequency: each 8 or 12 weeks
Study Details
Recently studies have shown that intravitreal injection of ranibizumab is effective for age related macular degeneration. However there are problems about injection regimen of maintenance phase. We plan to perform new simplified treat and extend regimen using ranibizumab.
Key Dates
- First listed
- Dec 31, 2014
- Start date
- Jun 30, 2014
- Status verified
- Dec 2014
- Primary completion
- Dec 31, 2016
- Completion
- Dec 31, 2016
Study Design
- Enrollment
- 50 participants (estimated)
- Allocation
- NA
- Intervention model
- SINGLE_GROUP
- Primary purpose
- TREATMENT
Arms
- Experimental: ranibizumabranibizumab
Primary Outcome Measure
A change from baselines best corrected visual acuity at 24 months [ Time Frame: 24 months ]